DelveInsight’s, “Advanced Liver Cancer Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced liver cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Advanced Liver Cancer Pipeline Report
- DelveInsight’s Advanced Liver Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Liver Cancer treatment.
- The leading Advanced Liver Cancer Companies such as Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd., and others.
- Promising Advanced Liver Cancer Therapies such as Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Parsaclisib, AV-299, Zimberelimab, Domvanalimab, and others.
- June 2024:- Hoffmann-La Roche- A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver). This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.
- June 2024:- Epizyme Inc.- A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies. The study will be conducted in 2 parts for subjects with advanced malignancies and either normal liver function, or advanced malignancies and moderate, or severe hepatic impairment. Subjects in Part 1 of the study will receive a single oral, 800 mg dose of tazemetostat on Day 1 and Day 15. In addition, the subjects will receive tazemetostat (oral 800 mg dose) tablets to be taken twice daily from Day 5 to Day 14.
Explore our comprehensive Advanced Liver Cancer Pipeline Report to stay informed about the latest advancements. Download copy now @ Advanced Liver Cancer Pipeline Outlook
Advanced Liver Cancer Overview
Advanced liver cancer, characterized by its progression to later stages, represents a formidable medical challenge due to its propensity for metastasis and the intricate interplay of factors influencing disease progression. At this advanced stage, the cancer has typically infiltrated surrounding tissues and organs, disrupting normal liver function and potentially impacting vital bodily processes. Metastasis, often widespread by this point, can occur in various distant sites beyond the liver, including the lungs, bones, lymph nodes, and other regions, exacerbating the complexity of disease management.
Advanced liver cancer Emerging Drugs
- Namodenoson: Can-Fite BioPharma
Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). Namodenoson’s mechanism of action is mediated via deregulation of the NF-?B and Wnt signal transduction pathways, resulting in the apoptosis of tumor cells. The protective effect of Namodenoson is mediated via down-regulation of the NF-kB signal transduction pathway and preventing apoptosis. Namodenoson has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation. Currently, the drug is in Phase III stage of its development for the treatment of Advanced liver Cancer.
- ADI-PEG20: Polaris Pharmaceuticals
Pegylated arginine deiminase (ADI-PEG20) is a novel anticancer enzyme that produces depletion of arginine, which is a nonessential amino acid in humans. Certain tumors, such as malignant melanoma and hepatocellular carcinoma, are auxotrophic for arginine. These tumors that are sensitive to arginine depletion do not express argininosuccinate synthetase, a key enzyme in the synthesis of arginine from citrulline. ADI-PEG20 appears to show inhibitory effects on human melanomas and hepatocellular carcinomas. Currently, the drug is in Phase III stage of its development for the treatment of Advanced liver Cancer.
- SRF388: Surface Oncology
SRF388 is a fully human IgG1 blocking antibody to IL-27 with potential to promote immune activation in the tumor microenvironment. The immunoregulatory cytokine IL-27 upregulates inhibitory immune checkpoint receptors (eg, PD-L1, TIGIT) and downregulates proinflammatory cytokines (eg, IFN?, TNFa). Currently, the drug is in the Phase II stage of development to treat Advanced liver cancer.
- TQB2223: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
TQB2223 is a recombinant, fully human antibody that binds to lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. Currently, the drug is in the Phase I stage of development to treat Advanced liver cancer.
Dive into our Advanced Liver Cancer Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ Advanced Liver Cancer Treatment Therapies
Advanced Liver Cancer Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Advanced liver cancer. The Advanced Liver Cancer companies which have their Advanced liver cancer drug candidates in the most advanced stage, i.e. Phase III include, Can-Fite BioPharma and Polaris Pharmaceuticals.
DelveInsight’s Advanced Liver Cancer pipeline report covers around 50+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Download the Advanced Liver Cancer Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ Advanced Liver Cancer Clinical Trials Assessment
Advanced liver cancer Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Advanced Liver Cancer Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Dive into our detailed Advanced Liver Cancer Pipeline Report to discover ground breaking advancements shaping the future of cancer treatment @ Advanced Liver Cancer Products, Companies, and Unmet Needs
Scope of the Advanced Liver Cancer Pipeline Report
- Coverage- Global
- Advanced Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Advanced Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Advanced Liver Cancer Companies- Can-Fite BioPharma, Polaris Pharmaceuticals, SOTIO Biotech, Surface Oncology, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AstraZeneca, Takeda, Arbele, ImmVira Pharma Co. Ltd, Vaxcell Bio, Eutilex, Biocity Biopharmaceutics Co., Ltd., Qilu Pharmaceutical Co., Ltd., OriCell Therapeutics Co., Ltd., TORL Biotherapeutics, LLC, Shanghai Henlius Biotech, TaiRx, Inc., Biocity Biopharmaceutics Co., Ltd., and others.
- Advanced Liver Cancer Therapies- Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Parsaclisib, AV-299, Zimberelimab, Domvanalimab, and others.
Gain valuable insights into emerging therapies and innovations with our Advanced Liver Cancer Pipeline Report @ Advanced Liver Cancer Market Drivers and Barriers, Future Perspectives and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Advanced liver cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Advanced liver cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Namodenoson: Can-Fite BioPharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Product Name: Company Name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- TQB2223: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Advanced liver cancer Key Companies
- Advanced liver cancer Key Products
- Advanced liver cancer- Unmet Needs
- Advanced liver cancer- Market Drivers and Barriers
- Advanced liver cancer- Future Perspectives and Conclusion
- Advanced liver cancer Analyst Views
- Advanced liver cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/